Multiple Transplantation of Bone Marrow Derived CD133 Cell in Cerebral Palsy
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01763255 |
Recruitment Status :
Completed
First Posted : January 8, 2013
Last Update Posted : April 25, 2014
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Cerebral palsy (CP) is condition, sometimes thought of as a group of disorders that can involve brain and nervous system functions such as movement, learning, hearing, seeing, and thinking.Cerebral palsy is caused by injuries or abnormalities of the brain. Most of these problems occur as the baby grows in the womb, but they can happen at any time during the first 2 years of life, while the baby's brain is still developing.Bone marrow derived stem cells are known as a effective therapy.
In this study the investigators evaluate the side effect of multiple intrathecal injection of bone marrow stem cell in patients with cerebral palsy.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Cerebral Palsy | Biological: stem cell intrathecal injection | Phase 1 Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 8 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | The Safety of Multiple Intrathecal Injection of Bone Marrow Derived CD133 Cells in Patients With Cerebral Palsy |
Study Start Date : | April 2012 |
Actual Primary Completion Date : | April 2014 |
Actual Study Completion Date : | April 2014 |

Arm | Intervention/treatment |
---|---|
Experimental: CD133 transplantation
The patients with cerebral palsy that underwent CD133 transplantation.
|
Biological: stem cell intrathecal injection
Intrathecal injection of Bone marrow derived CD133 cells
Other Name: Stem cell transplantation |
No Intervention: Control
The patients with cerebral palsy that underwent regular observation.
|
- motor dysfunction [ Time Frame: 6months ]Evaluation the motor dysfunction 6months after intrathecal injection.
- sensory dysfunction [ Time Frame: 6months ]Evaluation the sensory dysfunction after intrathecal injection of CD133 cells.
- unconsciousness [ Time Frame: 48hours ]Evaluation the rate of unconsciousness during 48hours after cell transplantation.
- fever [ Time Frame: 48hours ]Evaluation the symptom of infection like fever 48hours after cell transplantation.
- motor improvement [ Time Frame: 6months ]Measure the improvement of motor system by GMFM66.
- Balance improvement [ Time Frame: 6months ]Measure the balance improvement by BBS.
- Spasm [ Time Frame: 6months ]Evaluation the improvement of spasm after stem cell transplantation.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 4 Years to 12 Years (Child) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- diagnosis of spastic quadriplegic CP Children must be between the ages of 4 and 12 years Children must be cleared by an orthopedic surgeon for risk of hip subluxation or dislocation and cannot have significant scoliosis (curvature > 40 degrees) Children must be seizure-free or seizure controlled
Exclusion Criteria:
- Children who have a diagnosis of "mixed" types of CP (i.e. athetosis) or other movement disorders (i.e. ataxia) Children who have had a selective dorsal rhizotomy, are presently are receiving intrathecal Baclofen, or have changed their spasticity medications in the past 6 months.
Children who have a metallic or electrical implants

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01763255
Iran, Islamic Republic of | |
Royan Institute | |
Tehran, Iran, Islamic Republic of |
Study Chair: | Hamid Gourabi, PhD | Head of Royan Institute | |
Study Director: | Nasser Aghdami, MD,PhD | Head of Royan department of degenerative medicine,Head of Royan celltherapy center | |
Study Director: | Ali Reza Zali, MD | Head of Neurosurgery research center of Shahid Beheshti University |
Responsible Party: | Royan Institute |
ClinicalTrials.gov Identifier: | NCT01763255 |
Other Study ID Numbers: |
Royan-Nerve-003 |
First Posted: | January 8, 2013 Key Record Dates |
Last Update Posted: | April 25, 2014 |
Last Verified: | January 2011 |
cerebral palsy CD133 cells intrathecal injection |
Paralysis Cerebral Palsy Neurologic Manifestations Nervous System Diseases |
Brain Damage, Chronic Brain Diseases Central Nervous System Diseases |